

1 **A combined kinetic-mechanistic and computational study on the competitive formation of seven-**  
2 **versus five-membered platinacycles; the relevance of spectator halide ligands†**

3  
4  
5  
6 Gabriel Aullón,<sup>a</sup> Margarita Crespo,<sup>\*a</sup> Mercè Font-Bardia,<sup>b</sup> Jesús Jover,<sup>a</sup> Manuel Martínez<sup>\*a</sup> and Jack  
7 Pike<sup>a</sup>  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 <sup>a</sup>Departament de Química Inorgànica, Universitat de Barcelona, Martí i Franquès 1-11, E-08028  
23 Barcelona, Spain.

24 E-mail: [margarita.crespo@qi.ub.es](mailto:margarita.crespo@qi.ub.es),  
25 [manel.martinez@qi.ub.es](mailto:manel.martinez@qi.ub.es)  
26

27 <sup>b</sup>Unitat de Difracció de RX. Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB).  
28 Universitat de Barcelona., Solé i Sabarís 1-3, 08028-Barcelona, Spain  
29  
30  
31  
32

33

34 The metalation reactions between  $[\text{Pt}_2(4\text{-MeC}_6\text{H}_4)_4(\mu\text{-SEt}_2)_2]$  and  $2\text{-X,6-FC}_6\text{H}_3\text{CHvNCH}_2\text{CH}_2\text{NMe}_2$   
35 ( $\text{X} = \text{Br, Cl}$ ) have been studied. In all cases, seven-membered platinacycles are formed in a process that  
36 involves an initial reductive elimination from cyclometallated PtIV intermediate compounds,  $[\text{PtX}(4\text{-}$   
37  $\text{CH}_3\text{C}_6\text{H}_4)_2(\text{ArCHvNCH}_2\text{CH}_2\text{NMe}_2)]$  ( $\text{X} = \text{Br, Cl}$ ), followed by isomerization of the resulting PtII  
38 complexes and a final cyclometallation step. For the process with  $\text{X} = \text{Br}$ , the final seven-membered  
39 platinacycle and two intermediates, isolated under the conditions implemented from parallel kinetic  
40 studies, have been characterized by XRD. Contrary to previous results for the parent non-fluorinated  
41 imine  $2\text{-BrC}_6\text{H}_4\text{CHvNCH}_2\text{CH}_2\text{NMe}_2$  the presence of a fluoro substituent prevents the formation of the  
42 more stable five-membered platinacycle. Temperature and pressure dependent kinetic-mechanistic and  
43 DFT studies indicate that the final cyclometallation step is strongly influenced by the nature of the  
44 spectator halido ligand, the overall reaction being much faster for  $\text{X} = \text{Cl}$ . The same DFT study  
45 conducted on the previously studied systems with imine  $2\text{-BrC}_6\text{H}_4\text{CHvNCH}_2\text{CH}_2\text{NMe}_2$  indicates that,  
46 when possible, five-membered platinacycles are kinetically preferred for  $\text{X} = \text{Br}$ , while the presence of Cl  
47 as a spectator halido ligand leads to a preferential faster formation of seven-membered analogues.

48

49

## 50 INTRODUCTION

51

52 Reductive elimination reactions have attracted a great deal of interest since they may lead to the  
53 formation of new bonds, in either stoichiometric or catalytic transformations. In particular, Pt(IV)  
54 compounds are considered adequate models to study reductive elimination processes from d6 octahedral  
55 complexes. Recent findings based on reductive elimination from platinum(IV) complexes include the  
56 formation of C–C and C–halide bonds<sup>1</sup> and a catalytic process for conversion of a C–F bond into a C–C  
57 bond.<sup>2</sup> In particular, cyclometallated platinum(IV) compounds [PtXR<sub>2</sub>(Ar'CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>)] or  
58 [PtXR<sub>2</sub>(Ar'CHNCH<sub>2</sub>Ar')L] containing respectively a tridentate [C,N,N'] ligand or a bidentate [C,N]  
59 and a neutral monodentate L ligand can be easily obtained from the reactions of platinum precursors  
60 containing "PtR<sub>2</sub>" moieties and potentially tridentate or bidentate imine ligands,  
61 Ar'CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> or Ar'CHNCH<sub>2</sub>Ar'. In recent years, we have been involved in studies related to  
62 the formation of platinum(II) cyclometallated compounds generated from the mentioned platinum(IV)  
63 cyclometallated compounds with tridentate [C,N,N'] amino–imine ligands, or bidentate [C,N] imine  
64 ligands, and a neutral monodentate ligand L.<sup>3–12</sup> The interest in these reactions arises from the fact that  
65 along the process new C–C bonds are formed via an initial reductive elimination to give a  
66 noncyclometallated platinum(II) compound that, in the second step, evolves towards a cycloplatinated  
67 compound. Although a common sequence operates, this process is highly versatile since both the nature  
68 of the formed C–C bond and the structure of the final cyclometallated platinum(II) compound can be  
69 tuned by a judicious choice of both the platinum precursor "PtR<sub>2</sub>" and the imine ligand,  
70 Ar'CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> or Ar'CHNCH<sub>2</sub>Ar', used in the formation of the cyclometallated platinum(IV)  
71 compound. For instance, the reaction of [Pt<sub>2</sub>Me<sub>4</sub>(μ-SMe<sub>2</sub>)<sub>2</sub>] with imine ligands Ar'CHNCH<sub>2</sub>Ar' leads  
72 to a cyclometallated platinum(IV) compound from which Caryl–Calkyl bonds are formed and the  
73 subsequent metalation can lead to either five or six-membered metallacycles corresponding to C–H  
74 activation at the aryl group of the imine, or at the methyl ligand of the platinum precursor, respectively  
75 (Scheme 1).<sup>3,5</sup>

76 For diarylplatinum precursors, the corresponding platinum(IV) compounds lead to the formation of  
77 Caryl–Caryl bonds from which either seven-membered platinacycles containing the new biaryl fragment  
78 or five-membered analogues, in which the newly formed C–C bond is outside the metallacycle, can be  
79 obtained.<sup>4,6,7,9–12</sup> For the former, C–H bond activation takes place at the aryl ligand of the precursor,  
80 while for the latter this process takes place at the aryl ring of the imine. A clear example (Scheme 2) is  
81 obtained when cis-[Pt(C<sub>6</sub>F<sub>5</sub>)<sub>2</sub>(SEt<sub>2</sub>)<sub>2</sub>] is used, since, in this case, the ortho-fluorine substituents  
82 preclude the formation of seven-membered platinacycles, due to the low reactivity of C–F bonds, and  
83 therefore the reaction is directed towards the formation of five-membered analogues.<sup>8</sup>

84 A more striking result, shown in Scheme 3, was obtained in the reaction of [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>]  
85 with imines 2-XC<sub>6</sub>H<sub>4</sub>CH<sub>v</sub>NCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (X = Br or Cl) since, in this case, the nature of the halide is  
86 determinant: a five-membered platinacycle is obtained for X = Br, while a seven-membered platinacycle  
87 is produced for X = Cl. This system has been thoroughly studied from a kinetic-mechanistic point of  
88 view and although formation of a seven-membered platinacycle for X = Br was found plausible under  
89 harsher conditions, the compound could not be obtained in a pure form.<sup>4</sup>

90 Since seven-membered platinacycles are a novel class of compounds with potential interest associated  
91 with their cytotoxic properties,<sup>13,14</sup> in addition to the intrinsic interest based on the formation of biaryl  
92 linkages, we decided to explore novel strategies in order to analyse whether it would be possible to  
93 obtain such compounds even when X = Br. In this work, the reactions of [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>]  
94 with imines 2-X,6-FC<sub>6</sub>H<sub>3</sub>CH<sub>v</sub>NCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (X = Br or Cl) have been studied with the idea that the  
95 fluoro substituent at the ortho position in the aryl ring of the imine ligand should prevent the C–H bond  
96 activation at the imine and thus, in both cases, the reaction would be driven towards the formation of  
97 seven-membered platinacycles rather than five-membered analogues. It should be noted that five-

98 membered metallacycles are more stable than other ring products and generally cyclometallation  
99 reactions take place with high regioselectivity to produce five-membered rings.<sup>15–17</sup> Kinetic-  
100 mechanistic and DFT studies of these types of systems should allow studying the effect of the nature of  
101 the halide (Br versus Cl) in the formation of seven-membered platinumacycles.

102

## 103 RESULTS AND DISCUSSION

104

### 105 Preparation and characterisation of compounds

106 Initial platinum(IV) compounds [PtX(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>(2-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>)] (5-IV-X,F, X =  
107 Br and Cl; Scheme 4) were prepared in high yields, following previously established procedures, from  
108 [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>] and imines 2-X,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (X = Br and Cl).<sup>18</sup> For X  
109 = Br the reaction was faster and was complete within 24 hours in toluene solution at room temperature,  
110 while for X = Cl the reaction requires 48 hours under the same conditions. As expected from the lower  
111 reactivity of C–F bonds, activation of this bond was not observed in either reaction. Using shorter  
112 reaction times, isolation and characterisation of the coordination compound [Pt(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>(2-F,6-  
113 ClC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>)], formed prior to the intramolecular C–Cl bond activation has also been  
114 achieved; isolation of the corresponding bromo analogue has not been possible. In this case the  
115 intramolecular C–Br bond activation occurred readily after coordination of the imine ligand to platinum.  
116 All the isolated compounds were characterized by <sup>1</sup>H and <sup>19</sup>F NMR spectra, which were consistent  
117 with the expected structures as well as from the data available for analogous compounds.<sup>4,9</sup> As  
118 expected, the J(Himine–Pt) values observed for the platinum(IV) compounds (45.6 and 46.0 Hz) are  
119 lower than those observed for the platinum(II) compound [Pt(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>(2-F,6-  
120 ClC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>)] (50.8 Hz). For the latter, the J(Himine–Pt) value is consistent with both  
121 an E conformation of the imine moiety and the presence of an aryl ligand trans to this group.<sup>4</sup> A set of  
122 signals of very low intensity that could not be fully assigned indicated also the presence of a Z isomer in  
123 the sample in small amounts (<5%).

124 When a toluene solution of compound 5-IV-Br,F was refluxed for 24 hours, the targeted seven-  
125 membered platinacycle [PtBr{(4-MeC<sub>6</sub>H<sub>3</sub>)(2-FC<sub>6</sub>H<sub>3</sub>)CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (7-II-Br,F) was obtained.  
126 This compound could also be obtained in a onepot process from [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>] and the  
127 corresponding 2-Br,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> imine under the same conditions. These results  
128 indicate that the presence of an inert C–F bond in the imine ligand is an efficient strategy to drive the  
129 reaction towards the formation of seven-membered platinacycles. Formation of the analogue chlorido  
130 compound [PtCl{(4-MeC<sub>6</sub>H<sub>3</sub>)(2-FC<sub>6</sub>H<sub>3</sub>)CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (7-II-Cl,F) took place much more  
131 readily, since refluxing in toluene for 6 hours either a solution of the platinum(IV) compound 5-IV-Cl,F  
132 or a mixture of [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>] and imine 2-Cl,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, produced  
133 the desired compound. NMR data are in good agreement with those reported for analogous compounds  
134 with chlorido ligands.<sup>9,13</sup> The high value obtained for 3J(Himine–Pt) (150.4 Hz) is consistent with both  
135 the E conformation of the imine and the presence of an halide trans to the imino group.<sup>4</sup>

136 Suitable crystals of compound 7-II-Br,F were grown from dichloromethane–methanol at room  
137 temperature, and XRD analysis was possible from the crystals obtained, showing that the structure is  
138 composed of discrete molecules separated by van der Waals distances (Fig. 1a); selected bond data are  
139 listed in Table 1. The complex shows a square-planar coordination of the platinum(II) with a terdentate  
140 [C,N,N'] unit and a bromo ligand. The metallacycle consists of a non-planar seven-membered system in  
141 which the biaryl fragment and the imine functionality are included. Bond lengths and angles are well  
142 within the range of values obtained for analogous compounds,<sup>9,13</sup> the Pt–Br bond length being slightly  
143 longer than the reported Pt–Cl lengths for compounds of the same type. Most bond angles at platinum  
144 are close to the ideal value of 90°, and the smallest angle corresponds to the chelate N–Pt–N bite angle.

145 To confirm whether the formation of seven-membered platinacycles from the corresponding  
146 platinum(IV) cyclometallated compounds follows a common sequence, regardless of the presence of a  
147 chlorido or a bromido ligand, time-resolved experiments were conducted. A xylene solution of the  
148 complexes was monitored at different temperatures and times to ascertain the best set of conditions  
149 where the intermediates were present in representative amounts. Proton NMR studies revealed that after

150 stirring a solution of 5-IV-Br,F for 90 minutes at 70 °C, 90% of the sample had progressed to the  
151 dangling biphenyl intermediate form II-Br,F (Scheme 4). From the reaction mixture, suitable crystals of  
152 the intermediate could be obtained in its E form, allowing for full XRD characterization as its CH<sub>2</sub>Cl<sub>2</sub>  
153 solvato species. The relatively low value of 3J(Himine–Pt) (35.6 Hz) is in the range expected for  
154 compounds with an aryl ligand trans to the imino group and an E conformation of the imine.<sup>4</sup> The  
155 molecular structure is also shown in Fig. 1b and selected molecular dimensions are listed in Table 1. The  
156 square-planar coordination of the platinum(II) is achieved with a bidentate [N,N'] ligand, a bromido,  
157 trans to the dimethylamino moiety, and a para-tolyl ligand. The bond lengths and angles are well within  
158 the range of values obtained for analogous compounds.<sup>4</sup> Again, most of the bond angles at platinum are  
159 close to the ideal value of 90°, and the smallest angle corresponds to the chelate N–Pt–N bite angle. The  
160 crystal structure of this compound confirms that a biphenyl fragment involving a former para-tolyl  
161 ligand and the aryl ring of the initial ligand is formed from 5-IV-Br,F in a reductive elimination process.

162 As already reported, the compounds generated on reductive elimination on platinum(IV) compounds of  
163 the type 5-IV-X,Y may adopt four distinct isomeric forms (see Scheme 5); the aryl ring being trans to  
164 the amine or the imine moieties and with an E or Z imine conformation.<sup>4</sup> By monitoring changes in the  
165 <sup>1</sup>H NMR spectra of II-Br,F, under the conditions suggested by the kinetic experiments detailed in the  
166 next section, compound II'-Br,F, as a mixture of E and Z isomers in a proportion E : Z = 2 : 1, was  
167 obtained. As previously reported,<sup>4</sup> the values of J(Himine–Pt), which in this case are 152 Hz and 84 Hz  
168 for the E and Z isomers, respectively, indicate the presence of an halide ligand trans to the imine. From  
169 this mixture, XRD quality crystals were obtained and analysed; the molecular structure is shown in Fig.  
170 1c and selected molecular dimensions are listed in Table 1. This compound differs from the previously  
171 described intermediate in that the bromido ligand is now trans to the imino fragment, and the latter  
172 displays a Z arrangement. A careful examination of this Z isomeric form of the species results in clear  
173 evidence that this form cannot produce the final seven membered platinacycles for orientation reasons.  
174 A similar treatment carried out on compound II-Cl,F produced rather complex <sup>1</sup>H NMR spectra which  
175 consist of mixtures of up to four possible isomers of the species plus the initial and final reaction  
176 compounds (i.e. 5-IV-Cl,F and 7-II-Cl, F). From these complex mixtures, already anticipated from the  
177 data collected in the next section, it was not possible to isolate any of the relevant species.

178

### 179 **Kinetico-mechanistic studies on the formation of sevenmembered 7-II-Br,F and 7-II-Cl,F** 180 **metallacycles**

181 The rather complex nature of both the possible reaction intermediates and the nature of the final  
182 cyclometallated complexes formed in the reactions is generalised in Scheme 5. This general scheme is  
183 clear both from some previous results already published,<sup>4,19</sup> and those indicated in the previous section.  
184 Given the fact that time-resolved monitoring of the processes has been found to be a perfect handle to  
185 gain a better insight into the reaction mechanism, the UV-Vis monitoring of the transformation of  
186 complexes 5-IV-X,F has been conducted from a kinetic perspective.

187 For complex 5-IV-Br,F the spectral changes observed on monitoring 5 × 10<sup>-4</sup> M xylene solutions at  
188 varying temperatures indicate the operation of a two-step process in the 2–24 hour range at 90 and 60 °C  
189 respectively. By using the standard software indicated in the Experimental section, these changes could  
190 be easily fitted to a consecutive set of two single exponentials. From the time scale, as well as from  
191 parallel NMR monitoring, and the preparative procedures indicated before these processes correspond to  
192 the reductive elimination from 5-IV-Br,F to II-Br,F followed by isomerisation to II'-Br,F. The follow up  
193 final reaction to produce 7-II-Br,F could not be monitored due to the high temperature needed as well as  
194 for its time scale. Table 2 collects the relevant kinetic and activation data derived from the plots shown  
195 in Fig. 2a for the processes monitored, together with other relevant data for similar processes. The data  
196 indicate that the mechanism operating for the full process perfectly parallels that found for the reactivity  
197 of the similar 5-IV-Br,H, although in the present case the formation of the final five-membered

198 platinumacycle is hindered by the presence of the fluoro substituent at the remaining ortho position of the  
199 initial imine ligand. Formation of the seven membered 7-II-Br,F species is much slower, and it only  
200 occurs due to the blockage of the position leading to the 5-II-Br,H complex. From the thermal and  
201 pressure activation parameters it is clear that the reductive elimination reaction, i.e. 5-IV-Br,F  $\rightarrow$  II-  
202 Br,F, requires a rather large activation enthalpy with practically no changes in entropy, which indicates a  
203 transition state with a dominant breaking of the two Pt–C bonds, but keeping them organised by an  
204 incipient C–C bond making. This is the behaviour expected for this type of general reductive elimination  
205 reactions. As for the volume of activation (Fig. 2b), it is in line with a small compression, precisely due  
206 to the new C–C bond being formed. As for the II-Br, F  $\rightleftharpoons$  II'-Br,F isomerisation reaction monitored, the  
207 activation parameters agree perfectly well with those obtained for the already studied II-Br,H  $\rightleftharpoons$  II'-Br,H  
208 process. The values of the entropy and volume of activation are very negative, in line with a rather  
209 ordered and compressed transition state. Probably the highest point in the energy of the process  
210 corresponds to the formation of the new Pt–NMe<sub>2</sub> bond from a triangular-planar previously dissociated  
211 intermediate arrangement. Consequently, the value of the activation enthalpy for the process has to be  
212 rather low, as observed, given the non-limiting dissociation of the Pt–N bond.

213 The parallel study carried out on the 5-IV-Cl,F  $\rightarrow$  7-II-Cl,F process proved to be much more complex to  
214 be monitored. As indicated in the previous section, <sup>1</sup>H NMR monitoring of the process according to the  
215 time-resolved changes obtained by UV-Vis indicated that the presence of a mixture of the four isomeric  
216 forms plus the final species indicated in Scheme 5 is prevalent under all the reaction conditions. The  
217 slowest process of the three step sequence observed was associated with the II-Cl,F  $\rightleftharpoons$  II'-Cl,F reaction,  
218 as an increase of concentration of the II'-Cl,F form is observed at this time-scale by <sup>1</sup>H NMR  
219 monitoring; kinetics could be monitored with low methodological errors by UV-Vis. Contrarily, the  
220 initial fast reductive elimination reaction proved to be the most complicated to determine kinetically due  
221 to the low solubility of 5-IV-Cl,F in xylene at temperatures lower than 50 °C and the readiness of the  
222 process (see Table 2). Given the fact that the outcome of the full process under the conditions studied is  
223 the final 7-II-Cl,F the remaining step observed was associated with the oxidative II'-Cl,F  $\rightarrow$  7-II,Cl,F  
224 reaction. The kinetic and thermal activation parameters determined for all these sets of reactions are also  
225 indicated in Table 2 along with the results for the other relevant systems. Clearly the data agree very  
226 well with those observed for the similar systems studied. It is thus clear that the relative ease of  
227 formation of the final 7-II-X,F sevenmembered platinumacycles is dictated by the presence of a X = Br or  
228 X = Cl donor in the II'-X,F  $\rightarrow$  7-II,X,F reaction, while the II-X, Y  $\rightleftharpoons$  II'-X,Y isomerisation process does  
229 not distinguish between the different X and Y donors on the platinum centre.

230

### 231 DFT calculations

232 In view of the data collected in Table 2, DFT calculations have been conducted at 139 °C (xylene  
233 boiling point) in order to establish which of the reaction steps indicated in Scheme 5 could be  
234 responsible for the prevalence of the species 7-II-Cl,H and 7-II-Cl,Cl, while only the 5-II-Br,H complex  
235 is observed,<sup>4</sup> instead of the expected 7-II-Br,H. The results should be then extrapolated to the present  
236 situation, 7-II-Cl,F and 7-II-Br,F, where complexes of type 5-II-Br,F are not possible due to the  
237 blocking design effect of the ligand used. Initial DFT calculations indicate that all E forms of II-X,H and  
238 II'-X,H are lower in energy than their corresponding Z analogues (Table 3). Since the reaction leading to  
239 the final products proceeds via the E isomeric form of the II'-X,H intermediates (vide infra), Z isomers  
240 can be considered irrelevant to the reaction course. Furthermore, as indicated in the previous sections,  
241 the distal C–H bond is too far away from the platinum(II) centre to be relevant for the oxidative addition  
242 process. From the data in Table 3 it is clear that the energies of the II'-X,H intermediates are in all cases  
243 lower than those of the II-X,H species, indicating that an isomerization process should be expected, as  
244 observed experimentally. The isomerization transition state (TS\_Isom), involving a three coordinated  
245 platinum species with a dangling NMe<sub>2</sub> group (Fig. S1†), was also calculated and found to be around

246 140 kJ mol<sup>-1</sup> above II-X,H (see Table 3). The geometry of the calculated TS\_Isom involves a rather  
247 late C–Pt–Nimine angle (180° (II-X,H) → 130° (TS\_Isom) → 90° (II'-X, H)), in good agreement with  
248 the kinetic activation data obtained experimentally.

249 Once the most stable II'-X,H intermediate is formed, two possible selective parallel pathways, leading to  
250 the characterised metallacycles, are possible. The first one (Scheme 6, top) involves the oxidative  
251 addition of the C–HA bond at the platinum followed by the reductive elimination of toluene producing  
252 the five-membered platinacycle (5-II-X,H). The equivalent seven-membered platinacycle (7-II-X,H)  
253 would be obtained in a similar fashion whenever the C–HB bond is activated at the metal (Scheme 6,  
254 bottom). Given the fact that five-membered platinacycles are more stable than their seven-membered  
255 counterparts (the calculated free energy difference being 31.8 (X = Br) and 33.4 (X = Cl) kJ mol<sup>-1</sup>, as  
256 expected from simple standard considerations)<sup>17,19,20</sup> the obtention of the larger seven-membered  
257 platinacycle from the II'-Cl,H intermediate has to be due to kinetic preferences.

258 A close look at the energy barriers calculated for the formation of 5-II-Cl,H and 7-II-Cl,H reveals that  
259 the seven-membered product is, indeed, the favoured one. While the barriers obtained for the formation  
260 of the 5-II-Cl,H five-membered platinacycle are 128.4 (oxidative addition, TS\_CHA) and 155.6  
261 (reductive elimination, TS\_RE1) kJ mol<sup>-1</sup>, the formation of the seven-membered platinacycle  
262 compound, 7-II-Cl,H, produces 149.8 (TS\_CHB) and 149.1 (TS\_RE2) kJ mol<sup>-1</sup> equivalent barriers,  
263 which imply the lower overall energy requirements. For the bromido analogues the outcome of DFT  
264 calculations produces the opposite trend, with the barriers favouring the formation of the five-membered  
265 product (see Scheme 6). In this case the energy requirements for oxidative addition (TS\_CHA) and  
266 reductive elimination (TS\_RE1) for the smaller five-membered platinacycles are 119.6 and 141.5 kJ  
267 mol<sup>-1</sup> respectively, slightly lower than those found for the seven-membered product: 146.4 (TS\_CHB)  
268 and 145.1 (TS\_RE2) kJ mol<sup>-1</sup>. It may be argued that the final products could also be obtained from the  
269 II-X,H isomeric form, but higher barriers were obtained for these pathways both for X = Br and X = Cl.  
270 Other possible pathways such as those involving the C–H activation on the tetracoordinated square  
271 planar platinum centre of II'-X,H, or  $\sigma$ -CAM processes<sup>21</sup> leading to the final products, were also  
272 computed and found to be noncompetitive with the mechanism proposed here.

273 The results collected in Scheme 6, which are clearly in line with the experimental observations, have  
274 been used to build a qualitative kinetic simulation model of product formation over time. For this  
275 purpose, the relative free energy differences have been transformed into rate constants by using the  
276 Eyring–Polanyi equation (i.e.  $k = (kbT/h) \exp(-\Delta G^\ddagger/RT)$ ), and the product evolution over time, from  
277 II'-X,H, has been calculated (Fig. 3). As may be observed, at 139 °C the product distribution trend  
278 matches the experimental observations: 5-II-Br,H is produced with preference to 7-II-Br,H from II'-  
279 Br,H, whereas the inverse (7-II-Cl,H preferably to 5-II-Cl,H) is observed for II'-Cl, H. Although the  
280 time scale in Fig. 3 reasonably matches the values for X = Br (50% conversion after 24 h), for X = Cl  
281 there is more than an order of magnitude difference. Nevertheless, in this high energy range, this  
282 difference is easily overcome when the methodological errors involved in the DFT calculation (4–16 kJ  
283 mol<sup>-1</sup>) are taken into account.

284 The validity of the mechanism in Scheme 6 has also been confirmed by its use in the formation of the  
285 fluorinated compounds 7-II-Br,F and 7-II-Cl,F characterised in the present work, for which the  
286 formation of the five-membered platinacycle 5-II-X,F is not possible. The calculated energy  
287 requirements (Table S2<sup>†</sup>), although very similar, are slightly lower for the X = Cl system, indicating that  
288 the formation of 7-II-Cl,F should be definitively faster. In fact, the qualitative kinetic model indicates  
289 that 7-II-Cl,F is obtained around four times faster than 7-II-Br,F, practically the same difference as  
290 observed experimentally (Fig. S2<sup>†</sup>).

291



292 **CONCLUSIONS**

293

294 In this work, the mechanism of formation of seven-membered platinacycles, in preference to the more  
295 thermodynamically stable five-membered analogues, has been disclosed through combined kinetic-  
296 mechanistic and computational studies. Seven-membered platinacycles are formed as the kinetically  
297 favoured products in a process which involves the reductive elimination from cyclometallated  
298 platinum(IV) compounds [PtX(4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>)<sub>2</sub>(ArCH<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>)] (X = Br, Cl), followed by  
299 isomerization of the resulting platinum(II) compounds plus a final cyclometallation step. The results  
300 indicated that the nature of the spectator halido ligand X (X = Br or Cl) is determinant in the  
301 platinacycle size of reaction products. The presence of a bromido ligand slows down the formation of  
302 seven-membered platinacycles in such a way that the formation of the five-membered analogue becomes  
303 competitive unless the required metalation site is blocked with a fluoro substituent. Both kinetic-  
304 mechanistic and computational studies indicate that, contrary to previous suggestions, the isomerization  
305 step is not significantly affected by the nature of the halido ligand. On the contrary, all data are  
306 consistent with the fact that the final cyclometallation step is only dependent on the nature of the  
307 spectator halido ligand and this step is responsible for the nature of the final products. Therefore, five-  
308 membered platinacycles are preferred for Br, while the presence of a Cl leads to the formation of  
309 sevenmembered analogues.

310

## 311 EXPERIMENTAL

312

### 313 General procedures

314 Microanalyses were performed at the Centres Científics i Tecnològics (Universitat de Barcelona).  
315 Electrospray mass spectra were performed at the Servei d'Espectrometria de Masses (Universitat de  
316 Barcelona) using a LC/MSD-TOF spectrometer using H<sub>2</sub>O–CH<sub>3</sub>CN 1 : 1 to introduce the sample. NMR  
317 spectra were performed at the Unitat de RMN d'Alt Camp de la Universitat de Barcelona using a  
318 Mercury-400 spectrometer (1H, 400 MHz; 19F, 376.5 MHz) and referenced to SiMe<sub>4</sub> (1H) or CFC13  
319 (19F). The  $\delta$  values are given in ppm and J values in Hz. Abbreviations used: s = singlet; d = doublet; t  
320 = triplet; q = quartet; m = multiplet.

321

### 322 Preparation of complexes

323 The compounds [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>( $\mu$ -SEt<sub>2</sub>)<sub>2</sub>]<sub>22</sub> and 2-Cl,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> <sub>23</sub> were  
324 prepared as reported elsewhere. Compound 7-II-Cl,F has been previously reported.<sup>13</sup>

325 **2-Br,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (Chart 1).** To a solution of N,N-dimethylethylenediamine (0.22  
326 g, 2.4 × 10<sup>-3</sup> mol) in toluene was added 2-bromo,6-fluorobenzaldehyde (0.50 g, 2.7 × 10<sup>-3</sup> mol), and  
327 the solution was allowed to stir at room temperature for 70 minutes. The mixture was dried over  
328 Na<sub>2</sub>SO<sub>4</sub>, the solution was filtered, and the solvent was removed under vacuum to give the product.  
329 Yield: 0.65 g (97%). 1H NMR (CDCl<sub>3</sub>, 298 K),  $\delta$ : 8.47 [s, 1H, H1]; 7.40 [dd, 1H, 3J(H<sub>2</sub>–H<sub>4</sub>) = 8.0,  
330 H<sub>2</sub>]; 7.20 [td, 1H, 3J(H<sub>3</sub>–H<sub>4</sub>) = 3J(H<sub>3</sub>–F) = 8.0, 4J(H<sub>3</sub>–H<sub>2</sub>) = 5.6, H<sub>3</sub>]; 7.08 [td, 1H, 3J(H<sub>4</sub>–H<sub>2</sub>,3) =  
331 8.0, H<sub>4</sub>]; 3.82 [t, 2H, 3J(H<sub>5</sub>–H<sub>6</sub>) = 6.8, H<sub>5</sub>]; 2.69 [t, 2H, 3J(H<sub>6</sub>–H<sub>5</sub>) = 7.0, H<sub>6</sub>]; 2.32 [s, 6H, H<sub>7</sub>]. 19F  
332 NMR (CDCl<sub>3</sub>, 298 K),  $\delta$ : -111.70 [dd, 3J(F–H) = 10.4, 4J(F–H) = 6.0]. ESI-MS, m/z: 273.04 [M +  
333 H]<sup>+</sup>.

334 **[PtBr(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>{2-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (5-IV-Br,F, Chart 2).** A mixture of  
335 compounds [Pt<sub>2</sub>(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>( $\mu$ -SEt<sub>2</sub>)<sub>2</sub>] (100 mg, 1.06 × 10<sup>-4</sup> mol) and 2-Br,6-FC<sub>6</sub>H<sub>3</sub>CHv  
336 NCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (60 mg, 2.19 × 10<sup>-4</sup> mol) was dissolved in 20 ml of toluene and was left for stirring at  
337 room temperature for 24 hours. The solvent was removed under vacuum to yield an oily residue. The oil  
338 was treated with diethyl ether and upon removal of ether under vacuum a yellow powder was obtained.  
339 Yield: 123 mg (89%). 1H NMR (CDCl<sub>3</sub>, 298 K),  $\delta$ : 8.89 [s, 1H, 3J(Pt–H<sub>1</sub>) = 45.6, H<sub>1</sub>]; 7.55 [m, 2H,  
340 H<sub>2</sub>]; 6.94 [d, 2H, 3J(H<sub>3</sub>–H<sub>2</sub>) = 7.6, H<sub>3</sub>]; 6.70–6.65 [m, 4H, H<sub>4</sub>–H<sub>5</sub>]; 6.63 [m, 3H, H<sub>6</sub>–H<sub>8</sub>]; 4.46–4.37  
341 [m, 1H, H<sub>9</sub>]; 4.36–4.23 [m, 2H, H<sub>10</sub>]; 2.97 [s, 3H, 3J(Pt–H<sub>11</sub>) = 11.2, H<sub>11</sub>]; 2.89–2.82 [m, 1H, H<sub>9'</sub>];  
342 2.50 [s, 3H, 3J(Pt–H<sub>11'</sub>) = 16.0, H<sub>11'</sub>]; 2.34 [s, 3H, H<sub>12</sub>]; 2.15 [s, 3H, H<sub>13</sub>]. 19F NMR (CDCl<sub>3</sub>, 298  
343 K),  $\delta$ : -112.38 [dd, 3J(F–H) = 10.9, 4J(F–H) = 5.6]. Anal. Found (calcd for C<sub>25</sub>H<sub>28</sub>BrFN<sub>2</sub>Pt): C: 45.9  
344 (46.16); H: 4.7 (4.34); N: 4.4 (4.31).

345 **[PtBr{(4-MeC<sub>6</sub>H<sub>3</sub>)(2-FC<sub>6</sub>H<sub>3</sub>)CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (7-II-Br,F, Chart 3).** A solution of [Pt<sub>2</sub>(4-  
346 MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>( $\mu$ -SEt<sub>2</sub>)<sub>2</sub>] (51 mg, 5.45 × 10<sup>-5</sup> mol) and 2-Br,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (30 mg, 1.10  
347 × 10<sup>-4</sup> mol) in 40 ml of toluene was stirred under reflux for 24 hours. The solvent was removed under  
348 vacuum to yield a yellow powder solid. Yield: 40 mg (65%). 1H NMR (CDCl<sub>3</sub>, 298 K),  $\delta$ : 9.06 [s, 1H,  
349 3J(Pt–H<sub>1</sub>) = 150.4, H<sub>1</sub>]; 7.55 [td, 1H, 3J(H<sub>2</sub>–H<sub>3</sub>,5) = 8.0, 4J(H<sub>2</sub>–F) = 6.0, H<sub>2</sub>]; 7.48 [d, 1H, 3J(H<sub>5</sub>–H<sub>2</sub>)  
350 = 8.0, H<sub>5</sub>]; 7.23 [s, 1H, H<sub>3</sub>]; 7.02 [ddd, 1H, 3J(H<sub>4</sub>–F) = 10.0, 3J(H<sub>4</sub>–H<sub>2</sub>) = 8.0, 4J(H<sub>4</sub>–H<sub>2</sub>) = 1.0, H<sub>4</sub>];  
351 6.85 [d, 1H, 3J(H<sub>6</sub>–H<sub>7</sub>) = 8.0, H<sub>6</sub>]; 6.78 [dd, 1H, 3J(H<sub>7</sub>–H<sub>6</sub>) = 8.0, 4J(H<sub>7</sub>–H<sub>4</sub>) = 1.6, H<sub>7</sub>]; 4.51 [m, 1H,  
352 2J(H<sub>8</sub>–H<sub>8'</sub>) = 11.6, 3J(H<sub>8</sub>–H<sub>10</sub>,10') = 4.4, 4J(H<sub>8</sub>–H<sub>1</sub>) = 1.2, H<sub>8</sub>]; 3.88 [m, 1H, 2J(H<sub>8'</sub>–H<sub>8</sub>) = 12.0,  
353 3J(H<sub>8'</sub>–H<sub>10</sub>,10') = 4.0, 3J(Pt–H<sub>8'</sub>) = 61.2, H<sub>8'</sub>]; 3.04 [s, 3H, H<sub>9</sub>]; 2.76 [s, 3H, H<sub>9'</sub>]; 2.70–2.56 [m, 2H,  
354 H<sub>10</sub>,10']; 2.30 [s, 3H, H<sub>11</sub>]. 19F NMR (CDCl<sub>3</sub>, 298 K),  $\delta$ : -118.62 [ddd, 3J(F–H) = 11.2, 4J(F–H) =  
355 6.4, 5J(F–H) = 2.4]. Anal. Found (calcd for C<sub>18</sub>H<sub>20</sub>BrFN<sub>2</sub>Pt·H<sub>2</sub>O): C: 37.3 (37.51); H: 3.8 (3.85); N:  
356 4.8 (4.86).

357 **[Pt(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>{(2-F,6-ClC<sub>6</sub>H<sub>3</sub>)CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}], (Chart 4).** A solution of [Pt<sub>2</sub>(4-  
358 MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>] (199 mg, 2.13 × 10<sup>-4</sup> mol) and 2-Cl,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (98 mg,  
359 4.28 × 10<sup>-4</sup> mol) in 40 ml of toluene was stirred at room temperature for 4 hours. The solvent was  
360 removed under vacuum to yield yellow oil. The oil was treated with diethyl ether and upon removal of  
361 ether under vacuum a yellow powder was obtained. The yellow solid was recrystallised in  
362 dichloromethane–methanol to yield yellow crystals. Yield: 234 mg (91%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 298 K), E-  
363 isomer, δ: 8.71 [s, 1H, 3J (Pt–H1) = 50.8, H1]; 7.24 [d, 2H, 3J(H2–H6) = 8.0, H2]; 6.97 [dt, 1H, 3J(H3–  
364 H4,7) = 8.0, 4J (F–H3) = 6.0, H3]; 6.80 [d, 1H, 3J(H4–H3) = 8.0, H4]; 6.73 [d, 2H, 3J(H5–H8) = 8.0,  
365 H5]; 6.69 [d, 2H, 3J(H6–H2) = 8.0, H6]; 6.54 [t, 1H, 3J(H7–H3) = 3J(H7–F) = 8.8, H7]; 6.17 [d, 2H,  
366 3J(H8–H5) = 8.0, H8]; 4.15 [m, 2H, H9]; 2.78 [t, 2H, 3J(H10–H9) = 5.6, H10]; 2.63 [s, 6H, H11]; 2.13  
367 [s, 3H, H12]; 1.90 [s, 3H, H13]. Z-isomer, 8.41 [s, 1H, 3J (Pt–H1) = 32.0, H1]; 2.64 [s, 6H, H11]; 2.18  
368 [s, 3H, H12]. <sup>19</sup>F NMR (CDCl<sub>3</sub>, 298 K), δ: –108.08 [dd, 3J (F–H) = 9.2, 4J (F–H) = 6.0]. Anal. Found  
369 (calcd for C<sub>25</sub>H<sub>28</sub>ClF<sub>2</sub>N<sub>2</sub>Pt): C: 49.3 (49.55); H: 5.0 (4.66); N: 4.6 (4.62).

370 **[PtCl(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>{3-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (5-IV-Cl,F, Chart 5).** A solution of [Pt<sub>2</sub>(4-  
371 MeC<sub>6</sub>H<sub>4</sub>)<sub>4</sub>(μ-SEt<sub>2</sub>)<sub>2</sub>] (200 mg, 2.14 × 10<sup>-4</sup> mol) and 2-Cl,6-FC<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> (99 mg,  
372 4.32 × 10<sup>-4</sup> mol) in 40 ml of toluene was stirred at room temperature for 48 hours. The solvent was  
373 removed under vacuum to yield yellow oil. The oil was treated with diethyl ether and upon removal of  
374 ether under vacuum a yellow green powder was obtained. Yield: 208 mg (80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 298  
375 K), δ: 8.90 [d, 1H, 4J(H1–H10) = 1.6, 3J (Pt–H1) = 46.0, H1]; 7.48 [d, 2H, 3J(H2–H6) = 8.0, H2]; 7.31  
376 [m, 1H, H3]; 7.24 [dd, 1H, 3J(H4–H5) = 8.0, 4J(H4–H3) = 1.6, H4]; 7.09 [t, 1H, 3J(H5–H3,4) = 7.6,  
377 H5]; 6.95 [d, 2H, 3J(H6–H2) = 8.4, H6]; 6.73 [d, 2H, 3J(H7–H8) = 8.4, H7]; 6.64 [d, 2H, 3J(H8–H7) =  
378 8.4, H8]; 4.45–4.35 [m, 1H, H9]; 4.34–4.20 [m, 2H, H10]; 2.85 [s, 3H, 3J (Pt–H11) = 11.2, H11]; 2.81–  
379 2.73 [m, 1H, H9']; 2.51 [s, 3H 3J (Pt–H11') = 16.0, H11']; 2.34 [s, 3H, H12]; 2.15 [s, 3H, H13]. <sup>19</sup>F  
380 NMR (CDCl<sub>3</sub>, 298 K), δ: –112.42 [dd, 3J (F–H) = 10.4, 4J (F–H) = 5.6]. Anal. Found (calcd for  
381 C<sub>25</sub>H<sub>28</sub>ClF<sub>2</sub>N<sub>2</sub>Pt): C: 49.4 (49.55); H: 5.1 (4.66); N: 4.7 (4.62).

382 **E-[PtBr(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>{(4-MeC<sub>6</sub>H<sub>4</sub>)(2-FC<sub>6</sub>H<sub>3</sub>)CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (II-Br,F, Chart 6).** Compound  
383 [PtBr(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>{3F-C<sub>6</sub>H<sub>3</sub>CHvNCH<sub>2</sub>CH<sub>2</sub>N(Me)<sub>2</sub>}] (5-IV-Br,F) (50 mg, 7.69 × 10<sup>-5</sup> mol) was  
384 dissolved in 10 ml of toluene and stirred at 70 °C for 90 minutes. The solvent was removed to yield  
385 quantitatively a yellow solid (50 mg). The <sup>1</sup>H NMR spectrum recorded in CDCl<sub>3</sub> indicated 90%  
386 conversion of 5-IV-Br,F into II-Br,F. Recrystallization of the crude solid affords XRD quality crystals; a  
387 reproducible yield could not be obtained under these conditions. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 298 K), δ: 8.76 [s,  
388 1H, 3J (Pt–H1) = 35.6, H1]; 7.49 [d, 2H, 3J(H2–H4) = 8.0, H2]; 7.44 [td, 1H, 3J(H3–H5,7) = 8.0, 4J (F–  
389 H3) = 5.6, H3]; 7.30 [d, 2H, 3J(H4–H2) = 8.0, H4]; 7.14 [dd, 1H, 3J(H5–H3) = 8.0, 5J(H5–H6) = 0.8,  
390 H5]; 7.10 [d, 2H, 3J(H6–H8) = 8.0, H6]; 7.09 [m, 1H, H7]; 6.77 [d, 2H, 3J(H8–H6) = 8.0, H8]; 3.84 [t,  
391 2H, 3J(H9–H11) = 5.6, H9]; 2.73 [s, 3H, H10]; 2.61–2.54 [m, 2H, H11]; 2.47 [s, 3H, H10']; 2.41 [s, 3H,  
392 H12]; 2.23 [s, 3H, H13].

393 **E/Z-[PtBr(4-MeC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>{(4-MeC<sub>6</sub>H<sub>4</sub>)(2-FC<sub>6</sub>H<sub>3</sub>)CHNCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>}] (II'-Br,F).** A solution of 10  
394 mg of II-Br,F in toluene was heated at 90 °C for 24 hours. The solvent was removed and the <sup>1</sup>H NMR  
395 spectrum was recorded in CDCl<sub>3</sub>, indicating a nearly quantitative conversion of II-Br,F into II'-Br,F.  
396 Recrystallization of the crude solid (9 mg) affords XRD quality crystals of the Z-isomer; a reproducible  
397 yield could not be obtained under these conditions. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 298 K), E-isomer, δ: 8.84 [s, 1H,  
398 3J (Pt–H) = 152.0, H1]; 6.97 [d, 2H, 3J(H–H) = 8.0]; 6.62 [d, 1H, 3J(H–H) = 8.0]; 6.25 [d, 1H, 3J(H–H)  
399 = 8.0]; 4.23 [m, 2H]; 2.74 [s, 6H]; 2.41 [s, 3H]; 2.11 [s, 3H]. Z-isomer, δ: 8.22 [s, 1H, 3J (Pt–H1) =  
400 84.0, H1]; 7.43 [m, 1H]; 6.81 [d, 1H, 3J(H–H) = 8.0]; 6.58 [d, 1H, 3J(H–H) = 8.0]; 6.42 [d, 1H, 3J(H–H)  
401 = 8.0]; 3.42 [m, 2H]; 2.72 [s, 6H]; 2.44 [s, 3H]; 2.12 [s, 3H].

402

403

404 **X-ray structure analysis**

405 Prismatic crystals were selected and intensity data were measured on a D8 Venture system equipped  
406 with a multilayer monochromator and a Mo microfocus. The structure was solved using the Bruker  
407 SHELXTL software package, and refined using SHELXL.<sup>24</sup> All hydrogen atom positional parameters  
408 were computed and refined using a riding model, with an isotropic temperature factor equal to 1.2 times  
409 the equivalent temperature factor of the atom to which they are linked; further details are given in Table  
410 4.

411

412 **Kinetics**

413 The kinetic profiles for the reactions were followed by UV-Vis spectroscopy in the full 700–300 nm  
414 range on HP8452A or Cary50 instruments equipped with thermostated multicell transports. The  
415 observed rate constants were derived from absorbance versus time traces at the wavelengths where a  
416 maximum increase and/or decrease of absorbance were/was observed; alternatively the full spectral  
417 time—resolved changes were used. For the reactions carried out at varying pressures, the previously  
418 described pillbox cell and pressurising system<sup>25–28</sup> were used and the final treatment of data was the  
419 same as described before. The calculation of the observed rate constants from the absorbance versus  
420 time monitoring of reactions, studied under first order concentration conditions, was carried out using  
421 the SPECFIT or RecatLab software.<sup>29,30</sup> The general kinetic technique is that previously  
422 described.<sup>11,18,31</sup> Table S1<sup>†</sup> collects the kobs values for all the systems studied as a function of  
423 starting complex, pressures and temperatures studied. All post-run fittings were carried out by using the  
424 standard available commercial programs.

425

426 **Computational details**

427 All the structures have been optimized without restrictions in xylene using the B3LYP density  
428 functional<sup>32–34</sup> including the D3 version of Grimme's dispersion<sup>35</sup> as implemented in the Gaussian09  
429 package.<sup>36</sup> The standard 6-31G\* basis set<sup>37–39</sup> was used for all H, C, N, F, Cl and Br atoms; the Los  
430 Alamos National Laboratory double zeta basis set (LANL2DZ)<sup>39–41</sup> along with the associated ECP  
431 describing the core electrons, was employed for Pt. The (IEF-PCM) method,<sup>42,43</sup> including the radii  
432 and non-electrostatic terms for Truhlar and coworkers' SMD solvation model,<sup>44</sup> was employed. In all  
433 cases, frequency calculations were carried out to confirm the nature of stationary points and transition  
434 states, with none and one negative value, respectively. Additional single point calculations on the  
435 optimized geometries were employed to obtain improved solvated free energy values with larger basis  
436 sets at 139 °C, the boiling point of xylene. The aug-cc-pVTZ basis set including polarization and the  
437 associated electron core potential<sup>45,46</sup> was employed for Pt and Br whereas all the other atoms were  
438 described with the 6-311+G\*\* all-electron basis set.<sup>45,47,48</sup> All the free energy values reported in the  
439 text correspond to those obtained with the larger basis sets and can be found, along their relevant  
440 thermochemical terms, in Table S3.<sup>†</sup>

441 The kinetic models have been constructed with the Copasi software<sup>49</sup> using the deterministic (LSODA)  
442 method with relative and absolute tolerance values of 10<sup>-6</sup> and 10<sup>-12</sup>, respectively.

443

444 **ACKNOWLEDGEMENTS**

445

446 Financial support from the Spanish Ministerio de Economía y Competitividad (projects CTQ2012-  
447 37821-C02-01 and CTQ2009-11501) is acknowledged.

448

449 **REFERENCES**

450

- 451 1 A. Vigalok, *Acc. Chem. Res.*, 2015, 48, 238–247. 2 T. Wang, L. Keyes, B. O. Patrick and J. A.  
452 Love, *Organometallics*, 2012, 31, 1397–1407.
- 453 3 C. M. Anderson, M. Crespo, N. Kfoury, M. A. Weinstein and J. M. Tanski, *Organometallics*,  
454 2013, 32, 4199–4207.
- 455 4 P. V. Bernhardt, T. Calvet, M. Crespo, M. Font-Bardía, S. Jansat and M. Martínez, *Inorg.*  
456 *Chem.*, 2013, 52, 474–484.
- 457 5 M. Crespo, C. M. Anderson, N. Kfoury, M. Font-Bardía and T. Calvet, *Organometallics*, 2012,  
458 31, 4401–4404.
- 459 6 M. Crespo, M. Font-Bardía and T. Calvet, *Dalton Trans.*, 2011, 40, 9431–9438.
- 460 7 M. Crespo, T. Calvet and M. Font-Bardía, *Dalton Trans.*, 2010, 39, 6936–6938.
- 461 8 T. Calvet, M. Crespo, M. Font-Bardía, K. Gómez, G. González and M. Martínez,  
462 *Organometallics*, 2009, 28, 5096–5106.
- 463 9 R. Martín, M. Crespo, M. Font-Bardía and T. Calvet, *Organometallics*, 2009, 28, 587–597.
- 464 10 M. Crespo, M. Font-Bardía and X. Solans, *Organometallics*, 2004, 23, 1708–1713.
- 465 11 M. Font-Bardía, C. Gallego, M. Martínez and X. Solans, *Organometallics*, 2002, 21, 3305–3307.
- 466 12 C. Gallego, M. Martínez and V. S. Safont, *Organometallics*, 2007, 26, 527–537.
- 467 13 R. Cortés, M. Crespo, L. Davin, R. Martín, J. Quirante, D. Ruiz, R. Messeguer, C. Calvis, L.  
468 Baldomà, J. Badia, M. Font-Bardía, T. Calvet and M. Cascante, *Eur. J. Med. Chem.*, 2012, 54,  
469 557–566.
- 470 14 A. Escolà, M. Crespo, J. Quirante, R. Cortés, A. Jayaraman, J. Badía, L. Baldomà, T. Calvet, M.  
471 Font-Bardía and M. Cascante, *Organometallics*, 2014, 33, 1740–1750.
- 472 15 I. Omae in *Cyclometallation reactions: Five membered ring products as universal reagents*,  
473 Springer, 2014.
- 474 16 I. Omae, *Coord. Chem. Rev.*, 2014, 280, 84–95.
- 475 17 M. Albrecht, *Chem. Rev.*, 2009, 110, 576–623.
- 476 18 T. Calvet, M. Crespo, M. Font-Bardía, S. Jansat and M. Martínez, *Organometallics*, 2012, 31,  
477 4367–4373.
- 478 19 M. Crespo, M. Martínez, S. M. Nabavizadeh and M. Rashidi, *Coord. Chem. Rev.*, 2014, 279,  
479 115–140.
- 480 20 J. Granell and M. Martínez, *Dalton Trans.*, 2012, 41, 11243–11258.
- 481 21 R. N. Perutz and S. Sabo-Etienne, *Angew. Chem., Int. Ed.* 2007, 46, 2578–2592.
- 482 22 B. R. Steele and K. Vrieze, *Transition Met. Chem.*, 1977, 2, 169–174.
- 483 23 C. M. Anderson, M. Crespo, M. C. Jennings, A. J. Lough, G. Ferguson and R. J. Puddephatt,  
484 *Organometallics*, 1991, 10, 2672–2679.
- 485 24 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Fundam. Crystallogr.*, 2008, 64, 112–122.

486 25 R. van Eldik, in *Inorganic High Pressure Chemistry*, ed. R. van Eldik, Elsevier, 1986, pp. 1–68.

487 26 J. Garcia-Amorós, M. Martínez, H. Finkelman and D. Velasco, *J. Phys. Chem. B*, 2010, 114,  
488 1287–1293.

489 27 B. P. Macpherson, B. M. Alzoubi, P. V. Bernhardt, M. Martínez, P. Tregloan and R. van Eldik,  
490 *Dalton Trans.*, 2005, 1459–1467.

491 28 I. Favier, M. Gómez, J. Granell, M. Martínez, M. Font-Bardía and X. Solans, *Dalton Trans.*,  
492 2005, 123–132.

493 29 R. A. Binstead, A. D. Zuberbuhler and B. Jung, SPECFIT32. [3.0.34], Spectrum Software  
494 Associates, Marlborough, MA, USA, 2005.

495 30 M. Maeder and P. King, ReactLab, Jplus Consulting Pty Ltd, East Fremantle, WA, Australia,  
496 2009.

497 31 G. D. Roiban, E. Serrano, T. Soler, G. Aullón, I. Grosu, C. Cativiela, M. Martínez and E. P.  
498 Urriolabeitia, *Inorg. Chem*, 2011, 50, 8132–8143.

499 32 A. D. Becke, *J. Chem. Phys.*, 1993, 98, 5648–5652.

500 33 C. Lee, W. Yang and R. G. Parr, *Phys. Rev. B: Condens. Matter*, 1988, 37, 785–789.

501 34 B. Miechlich, A. Sauvin, H. Stoll and H. Preuss, *Chem. Phys. Lett.*, 1989, 157, 200–206.

502 35 J. Grimme, J. Anthony, S. Ehrlich and H. Krieg, *J. Chem. Phys.*, 2010, 132, 154104.

503 36 M. J. Frisch, et al., GAUSSIAN 09 (Revision CD.01), Gaussian Inc., Wallingford CT, 2009.

504 37 P. C. Hariharan and J. A. Pople, *Theor. Chim. Acta*, 1973, 28, 213–222.

505 38 M. M. Francl, W. J. Pietro, W. J. Hehre, J. S. Binkley, M. S. Gordon, D. J. DeFrees and J. A.  
506 Pople, *J. Chem. Phys.*, 1982, 77, 3654–3665.

507 39 V. Rassolov, J. A. Pople, M. Ratner and T. L. Windus, *J. Chem. Phys.*, 1998, 109, 1223–1229.

508 40 P. J. Hay and W. R. Wadt, *J. Chem. Phys.*, 1985, 82, 299–310.

509 41 P. J. Hay and W. R. Wadt, *J. Chem. Phys.*, 1985, 82, 270–283.

510 42 D. J. Tannor, B. Marten, R. Murphy, R. A. Friesner, D. Sitkoff, A. Nicholls, B. Honig, M.  
511 Ringnalda and W. A. Goddard, *J. Am. Chem. Soc.*, 1994, 116, 11875–11882.

512 43 B. Marten, K. Kim, C. Cortis, R. A. Friesner, R. B. Murphy, M. N. Ringnalda, D. Sitkoff and B.  
513 Honig, *J. Phys. Chem.*, 1996, 100, 11775–11788.

514 44 A. V. Marenich, C. J. Cramer and D. G. Truhlar, *J. Phys. Chem. B*, 2009, 113, 6378–6396.

515 45 K. A. Peterson, D. Figgen, E. Goll, H. Stoll and M. Dolg, *J. Chem. Phys.*, 2003, 119, 11113–  
516 11123.

517 46 D. Figgen, K. A. Peterson, M. Dolg and H. Stoll, *J. Chem. Phys.*, 2009, 130, 164108–164112.

518 47 A. D. McLean and G. S. Chandler, *J. Chem. Phys.*, 1980, 72, 5639–5648.

519 48 R. Krishnan, J. S. Binkley, R. Seeger and J. A. Pople, *J. Chem. Phys.*, 1980, 72, 650–654.

520 49 S. Hoops, S. Sahle, R. Gauges, C. Lee, J. Pahle, N. Simus, M. Singhal, L. Xu, P. Mendes and U.  
521 Kummer, *Bioinformatics*, 2006, 22, 3067–3074.

522 .

523 **Legends to figures**

524

525 **Figure 1** Molecular structures of compounds (a) 7-II-Br,F, (b) II-Br,F (E form), and (c) II'-Br,F (Z  
526 form); hydrogen atoms have been omitted for clarity.

527

528 **Figure 2.** a) Eyring plot (60–90 °C) for the dependence of the rate constants of the steps monitored by  
529 UV-Vis spectroscopy on the 5-IV-Br,F → 7-II-Br,F reaction. (b) Pressure dependence  $\ln k$  versus P for  
530 the same processes.

531


532 **Figure 3** Qualitative product concentration evolution over time for II'-X,H (X = Br, Cl) on the arbitrary  
533 time scale.

534



535  
536  
537

### SCHEME 1




538  
539

540

### SCHEME 2

541

542




543

544

545



546  
547  
548  
549

### SCHEME 3



552  
553  
554

SCHEME4



Nomenclature (7, 5)-(II, IV)-X,Y for the complexes indicates:

Number of members of the metallacycle for cyclometallated complexes (7, 5)

Oxidation state of the Platinum centre (II, IV)


Halide ligand attached to the Platinum centre (X)

Substituent in the non-metallated *ortho* position of the  $\text{ArCH=NCH}_2\text{CH}_2\text{NMe}_2$  ligand (Y)

555  
556

557  
558  
559  
560


FIGURE 1.



561  
562

563  
564  
565

Scheme 5




566


567  
568  
569

FIGURE 2.

a)




b)



570  
571

572  
573  
574

### SCHEME 6




575  
576



577  
578  
579


FIGURE 3.



580  
581


CHART 1

582  
583  
584  
585



586  
587  
588  
589


CHART 2



593  
594  
595  
596  
597  
598

599  
600  
601


CHART 3



602  
603  
604

605  
606  
607

### CHART 4



608  
609  
610  
611  
612

613  
614  
615


### CHART 5



616  
617  
618  
619

620  
621

### CHART 6



622  
623

624 **Table 1.** Selected bond lengths (Å) and angles (°) for the structures determined for compounds 7-II-  
 625 Br,F, II-Br,F (E form), and II'-Br,F (Z form)

626

7-II-Br,F		II-Br,F (E form)		II'-Br,F (Z form)	
Pt(1)-C(1)	1.989(5)	Pt(1)-C(19)	2.002(7)	Pt(1)-C(1)	2.001(6)
Pt(1)-N(2)	2.001(5)	Pt(1)-N(2)	2.099(6)	Pt(1)-N(1)	2.025(5)
Pt(1)-N(1)	2.209(5)	Pt(1)-N(1)	2.103(6)	Pt(1)-N(2)	2.189(5)
Pt(1)-Br(1)	2.4352(6)	Pt(1)-Br(1)	2.4338(8)	Pt(1)-Br(1)	2.4265(7)
N(1)-C(15)	1.494(7)	N(1)-C(13)	1.271(9)	N(1)-C(8)	1.271(7)
N(2)-C(13)	1.278(7)	N(1)-C(14)	1.467(10)	N(1)-C(23)	1.484(8)
N(2)-C(14)	1.478(7)	N(2)-C(15)	1.506(10)	N(2)-C(24)	1.487(8)
C(1)-C(6)	1.413(7)	C(14)-C(15)	1.510(11)	C(23)-C(24)	1.506(9)
C(6)-C(7)	1.488(7)	C(19)-Pt(1)-N(2)	93.7(3)	C(1)-Pt(1)-N(1)	93.9(2)
C(7)-C(12)	1.408(8)	N(2)-Pt(1)-N(1)	82.0(2)	N(1)-Pt(1)-N(2)	82.9(2)
C(12)-C(13)	1.474(8)	C(19)-Pt(1)-Br(1)	88.0(2)	C(1)-Pt(1)-Br(1)	89.51(15)
C(14)-C(15)	1.511(8)	N(1)-Pt(1)-Br(1)	96.32(17)	N(2)-Pt(1)-Br(1)	93.68(14)
C(1)-Pt(1)-N(2)	91.8(2)				
N(2)-Pt(1)-N(1)	83.00(18)				
C(1)-Pt(1)-Br(1)	93.76(15)				
N(1)-Pt(1)-Br(1)	92.20(12)				

627

628

629

630

631



632 **Table 2** Kinetic and thermal activation parameters for the two reaction steps observed for the reaction of  
 633 different 5-IV-X,Y leading to 7-II-X,Y according to Scheme 5 in xylene solution. \* indicates a mixture  
 634 of II-X,Y and II'-X,Y isomers<sup>7</sup>

635

Reaction	Assignment	$10^3 \times {}^{340}k/s^{-1}$	$\Delta H^\ddagger/kJ\ mol^{-1}$	$\Delta S^\ddagger/J\ K^{-1}\ mol^{-1}$	$\Delta V^\ddagger/cm^3\ mol^{-1}$
5-IV-Cl <sub>2</sub> H → 7-II-Cl <sub>2</sub> H <sup>†</sup>	5-IV-Cl <sub>2</sub> H → II-Cl <sub>2</sub> H*	9.1	122 ± 5	33 ± 13	Not determined
	II-Cl <sub>2</sub> H* → 7-II-Cl <sub>2</sub> H	0.29	141 ± 15	60 ± 44	Not determined
5-IV-Cl <sub>2</sub> Cl → 7-II-Cl <sub>2</sub> Cl <sup>†</sup>	5-IV-Cl <sub>2</sub> Cl → II-Cl <sub>2</sub> Cl*	3.4	118 ± 5	13 ± 13	Not determined
	II-Cl <sub>2</sub> Cl* → 7-II-Cl <sub>2</sub> Cl	29	102 ± 5	-16 ± 15	Not determined
5-IV-Br <sub>2</sub> H → 5-II-Br <sub>2</sub> H <sup>†</sup>	5-IV-Br <sub>2</sub> H → II-Br <sub>2</sub> H	240	97 ± 4	-13 ± 11	Not determined
	II-Br <sub>2</sub> H ⇌ II'-Br <sub>2</sub> H	150	42 ± 5	-179 ± 15	Not determined
	II-Br <sub>2</sub> H* → 5-II-Br <sub>2</sub> H	30	86 ± 7	-63 ± 20	Not determined
5-IV-Br <sub>2</sub> F → 7-II-Br <sub>2</sub> F <sup>this work</sup>	5-IV-Br <sub>2</sub> F → II-Br <sub>2</sub> F	7.1	121 ± 2	28 ± 7	-9 ± 2 at 333 K
	II-Br <sub>2</sub> F ⇌ II'-Br <sub>2</sub> F	7.1	54 ± 4	-169 ± 12	-24 ± 4 at 328 K
5-IV-Cl <sub>2</sub> F → 7-II-Cl <sub>2</sub> F <sup>this work</sup>	5-IV-Cl <sub>2</sub> F → II-Cl <sub>2</sub> F	55 000	69 ± 15	-50 ± 45	Not determined
	II-Cl <sub>2</sub> F ⇌ II'-Cl <sub>2</sub> F	1.8	63 ± 5	-154 ± 13	Not determined
	II'-Cl <sub>2</sub> F → 7-II-Cl <sub>2</sub> F	2200	106 ± 15	32 ± 40	Not determined

636

637

638

639

640

641 **Table 3** Computed relative free energies (kJ mol<sup>-1</sup> at 139 °C) for the E and Z forms of the II-X,H and  
642 II'-X,H compounds indicated in Scheme 5

643

	X = Br		X = Cl	
	<i>E</i> form	<i>Z</i> form	<i>E</i> form	<i>Z</i> form
II-X,H	17.0	15.8	33.0	32.3
TS_Isom	138.4	Not calculated	140.1	Not calculated
II'-X,H	0	7.5	0	12.1

644

645

646

647 **Table 4** Crystallographic and refinement data for compounds 7-II-Br,F, II-Br,F (E form), and II'-Br,F  
 648 (Z form)  
 649

	7-II-Br,F	II-Br,F (E form)	II-Br,F (Z form)
Formula	C <sub>18</sub> H <sub>20</sub> BrFN <sub>2</sub> Pt	C <sub>25</sub> H <sub>20</sub> BrFN <sub>2</sub> Pt	C <sub>25</sub> H <sub>20</sub> BrFN <sub>2</sub> Pt
Pw	558.36	735.42	735.42
Temp., K	100 (K)	100(2)	100(2)
Wavelength	0.71073	0.71073	0.71073
Crystal system	Monoclinic	Monoclinic	Monoclinic
Space group	P2 <sub>1</sub> /c	C2/c	C2/c
a	10.1118(10)	27.163(2)	26.7638(14)
b	28.201(3)	15.4717(11)	13.0691(7)
c	15.4709(13)	13.4316(11)	15.8211(8)
β, °	127.177(5)	109.882(3)	117.052(2)
V, Å <sup>3</sup>	3515.1(6) 8	5308.4(7) 8	4928.4(5) 8
d (calcd)	2.11	1.84	1.753
Abs. Coeff., mm	10.266	7.018	7.336
F(000)	2112	2848	2512
Rfins coll./unique	52 682/8740	75 357/6599	70 645/8610
	[R(int) = 0.0635]	[R(int) = 0.0871]	[R(int) = 0.0702]
Data/restraint/parameter	8740/1/421	6599/0/302	8610/1/275
GOF on F	1.113	1.097	1.045
Final R [I > 2σ(I)]	R <sub>1</sub> = 0.0390	R <sub>1</sub> = 0.0569	R <sub>1</sub> = 0.0562
	wR <sub>2</sub> = 0.0593	wR <sub>2</sub> = 0.1050	wR <sub>2</sub> = 0.0969
R (all data)	R <sub>1</sub> = 0.0557	R <sub>1</sub> = 0.0738	R <sub>1</sub> = 0.0883
	wR <sub>2</sub> = 0.0642	wR <sub>2</sub> = 0.1120	wR <sub>2</sub> = 0.1094
Peak and hole	1.058 and -1.033	5.981 and -1.677	4.455 and -2.517
CDC number	1051232	1051233	1051234